Apellis Pharmaceuticals financials at a glance

+ Portfolio

The revenue of Apellis Pharmaceuticals is reported as 0.39659 billion Dollars in the fiscal year 2023. The earnings were -4.45 Dollars per share in 2023, which was 23.8 higher than 2022. And about -0.59551 billion Dollars are reported as free cash flow in the financials of Apellis Pharmaceuticals 2023. No dividends were paid to the shareholders of the Apellis Pharmaceuticals stock NasdaqGS:APLS in the financial year 2023.

$396.59M

Revenue

$-4.45

Earnings Per Share

-4.11%

Gross Margin %

$-,622.03M

Free Cash Flow

Revenue

396.59

Earnings Per Share

-4.45

Gross Margin %

-4.11

Free Cash Flow

-,622.03

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2016
Rev.	Revenue	N/A	$396.59M	$75.42M	$66.56M	$250.65M	$0.00M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	85.78%	-4.11%	92.53%	-20.49%	-29.65%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	-,218.65%	-,130.39%	0.00%	0.00%	-85.27%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-5.22	$-4.45	$-5.84	$-6.49	$-3.22	$-4.63	$-2.35	$-3.67	$-0.70
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	0
Sha.	Shares	N/AM	120.58M	111.29M	97.73M	80.38M	75.32M	56.28M	50.37M	8.43M
OCF	Operating Cash Flow	N/A	$-,594.74M	$-,513.75M	$-,563.13M	$-,160.49M	$-,211.14M	$-,131.24M	$-46.60M	$0.00M
FCF	Free Cash Flow	N/A	$-,622.03M	$-,515.27M	$-,564.23M	$-,165.91M	$-,212.83M	$-,131.24M	$-46.60M	$0.00M
FCFS	Free Cash Flow Per Share	$-5.51	$-5.02	$-4.86	$-6.68	$-2.21	$-3.42	$-2.41	$-3.36	$0.00

Apellis Pharmaceuticals financials at a glance

Financials

Discover